Galeon's Groundbreaking Funding for Drug Repurposing in Medical Research

Wednesday, 3 April 2024, 15:00

Galeon, an AI-powered health project, secures €500,000 in funding to support drug repurposing without any counterpart funds required. This initiative aims to accelerate the validation of repurposed drugs for new diseases under the DeSci (Decentralized Science) framework. By leveraging decentralized funding models, Galeon pioneers a community-driven approach to foster scientific innovation in medical research.
https://store.livarava.com/a2226779-f1ce-11ee-894f-87cc5c87fb08.jpg
Galeon's Groundbreaking Funding for Drug Repurposing in Medical Research

Repurposing Drugs for Maximum DeSci Impact

Repurposing existing drugs for new diseases holds immense promise for faster and more affordable treatments. However, traditional funding models often fall short due to centralized control and misaligned priorities. Galeon's DeSci approach disrupts this paradigm.

Galeon Pioneers: A Community of Scientific Innovators

Galeon's vision is to decentralize access to secure medical data across hospitals, fostering a global community of passionate researchers and innovators – the Galeon Pioneers. This empowers a collaborative environment where scientific innovation thrives.

Community-Driven Funding: DAO for Promising Research

Galeon is seeking promising drug repurposing candidates. Up to €500,000 will be allocated to fund essential studies, with projects selected by an independent scientific committee. Uniquely, Galeon's DAO, co-governed by patients (50%) and $GALEON token holders (50%), will also participate in the selection process. This DAO ensures funding is directed towards research with the greatest potential to benefit patients.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe